QQQ   414.73 (-2.05%)
AAPL   165.11 (-1.16%)
MSFT   399.28 (-1.23%)
META   479.55 (-4.43%)
GOOGL   153.82 (-1.40%)
AMZN   174.34 (-2.72%)
TSLA   146.98 (-1.97%)
NVDA   769.00 (-9.18%)
AMD   146.18 (-5.74%)
NIO   3.81 (-4.75%)
BABA   69.05 (+0.25%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   106.48 (-4.87%)
GE   148.44 (-2.94%)
CGC   8.05 (+2.81%)
DIS   112.31 (-0.11%)
AMC   3.13 (+7.19%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.97 (+1.22%)
QQQ   414.73 (-2.05%)
AAPL   165.11 (-1.16%)
MSFT   399.28 (-1.23%)
META   479.55 (-4.43%)
GOOGL   153.82 (-1.40%)
AMZN   174.34 (-2.72%)
TSLA   146.98 (-1.97%)
NVDA   769.00 (-9.18%)
AMD   146.18 (-5.74%)
NIO   3.81 (-4.75%)
BABA   69.05 (+0.25%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   106.48 (-4.87%)
GE   148.44 (-2.94%)
CGC   8.05 (+2.81%)
DIS   112.31 (-0.11%)
AMC   3.13 (+7.19%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.97 (+1.22%)
QQQ   414.73 (-2.05%)
AAPL   165.11 (-1.16%)
MSFT   399.28 (-1.23%)
META   479.55 (-4.43%)
GOOGL   153.82 (-1.40%)
AMZN   174.34 (-2.72%)
TSLA   146.98 (-1.97%)
NVDA   769.00 (-9.18%)
AMD   146.18 (-5.74%)
NIO   3.81 (-4.75%)
BABA   69.05 (+0.25%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   106.48 (-4.87%)
GE   148.44 (-2.94%)
CGC   8.05 (+2.81%)
DIS   112.31 (-0.11%)
AMC   3.13 (+7.19%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.97 (+1.22%)
QQQ   414.73 (-2.05%)
AAPL   165.11 (-1.16%)
MSFT   399.28 (-1.23%)
META   479.55 (-4.43%)
GOOGL   153.82 (-1.40%)
AMZN   174.34 (-2.72%)
TSLA   146.98 (-1.97%)
NVDA   769.00 (-9.18%)
AMD   146.18 (-5.74%)
NIO   3.81 (-4.75%)
BABA   69.05 (+0.25%)
T   16.45 (+0.73%)
F   12.11 (+0.41%)
MU   106.48 (-4.87%)
GE   148.44 (-2.94%)
CGC   8.05 (+2.81%)
DIS   112.31 (-0.11%)
AMC   3.13 (+7.19%)
PFE   25.96 (+2.24%)
PYPL   61.96 (-0.23%)
XOM   119.97 (+1.22%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$15.62
-1.5%
$17.50
$8.92
$24.50
$707.59M1.67403,459 shs277,362 shs
Natus Medical Incorporated stock logo
NTUS
Natus Medical
$32.96
$32.96
$20.90
$33.93
$1.14B0.22325,002 shs1,514 shs
Outset Medical, Inc. stock logo
OM
Outset Medical
$2.31
+2.7%
$2.66
$1.92
$24.13
$119.43M1.991.05 million shs662,222 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$83.97
-3.7%
$82.97
$36.42
$99.63
$2.75B1.99689,000 shs731,679 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
+4.76%-7.25%-10.09%-7.63%-19.86%
Natus Medical Incorporated stock logo
NTUS
Natus Medical
0.00%0.00%0.00%0.00%0.00%
Outset Medical, Inc. stock logo
OM
Outset Medical
+4.17%-1.10%0.00%-37.67%-87.44%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-0.71%-7.14%+18.56%+6.16%+20.13%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
1.6924 of 5 stars
3.51.00.00.02.02.50.6
Natus Medical Incorporated stock logo
NTUS
Natus Medical
N/AN/AN/AN/AN/AN/AN/AN/A
Outset Medical, Inc. stock logo
OM
Outset Medical
1.9832 of 5 stars
3.22.00.00.03.20.81.3
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
0.7645 of 5 stars
2.41.00.00.01.82.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
3.00
Buy$23.4049.81% Upside
Natus Medical Incorporated stock logo
NTUS
Natus Medical
N/AN/AN/AN/A
Outset Medical, Inc. stock logo
OM
Outset Medical
2.33
Hold$5.42134.49% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.86
Moderate Buy$102.0021.47% Upside

Current Analyst Ratings

Latest BLFS, NTUS, TMDX, and OM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/8/2024
Outset Medical, Inc. stock logo
OM
Outset Medical
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
4/5/2024
Outset Medical, Inc. stock logo
OM
Outset Medical
CL King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$6.00
4/4/2024
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$22.00
3/28/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$95.00
2/28/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$75.00 ➝ $95.00
2/27/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$87.00 ➝ $105.00
2/27/2024
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$92.00 ➝ $105.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$143.27M4.94N/AN/A$7.67 per share2.04
Natus Medical Incorporated stock logo
NTUS
Natus Medical
$473.44M2.41$2.02 per share16.34$12.44 per share2.65
Outset Medical, Inc. stock logo
OM
Outset Medical
$130.38M0.92N/AN/A$2.45 per share0.94
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$241.62M11.37$0.14 per share617.26$4.20 per share19.99

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$66.43M-$1.52N/AN/AN/A-46.37%-13.36%-10.83%5/8/2024 (Estimated)
Natus Medical Incorporated stock logo
NTUS
Natus Medical
$13.18M$0.3789.0820.99N/A2.65%10.15%7.65%N/A
Outset Medical, Inc. stock logo
OM
Outset Medical
-$172.80M-$3.50N/AN/AN/A-132.54%-102.50%-52.42%5/1/2024 (Estimated)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$25.03M-$0.77N/A204.80N/A-10.36%-2.35%-0.60%4/30/2024 (Confirmed)

Latest BLFS, NTUS, TMDX, and OM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2024N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$0.05N/A+$0.05N/AN/AN/A  
2/29/2024Q4 2023
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.24-$0.22+$0.02-$0.14$32.70 million$32.73 million
2/26/2024Q4 2023
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$0.10$0.12+$0.22$0.12$68.49 million$81.20 million    
2/21/2024Q4 2023
Outset Medical, Inc. stock logo
OM
Outset Medical
-$0.74-$0.77-$0.03-$0.77$30.40 million$30.51 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/AN/AN/AN/AN/A
Natus Medical Incorporated stock logo
NTUS
Natus Medical
N/AN/AN/AN/AN/A
Outset Medical, Inc. stock logo
OM
Outset Medical
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
0.06
2.86
1.83
Natus Medical Incorporated stock logo
NTUS
Natus Medical
N/A
2.54
1.90
Outset Medical, Inc. stock logo
OM
Outset Medical
1.06
5.26
4.37
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
3.69
9.30
8.49

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
93.24%
Natus Medical Incorporated stock logo
NTUS
Natus Medical
92.35%
Outset Medical, Inc. stock logo
OM
Outset Medical
N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.70%
Natus Medical Incorporated stock logo
NTUS
Natus Medical
1.20%
Outset Medical, Inc. stock logo
OM
Outset Medical
3.70%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
6.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
40945.30 million44.08 millionOptionable
Natus Medical Incorporated stock logo
NTUS
Natus Medical
1,40034.58 million34.17 millionOptionable
Outset Medical, Inc. stock logo
OM
Outset Medical
48051.70 million49.79 millionNot Optionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
58432.71 million30.52 millionOptionable

BLFS, NTUS, TMDX, and OM Headlines

SourceHeadline
TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein Sells 4,000 SharesTransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein Sells 4,000 Shares
insidertrades.com - April 19 at 6:50 AM
453,615 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Bought by Mackenzie Financial Corp453,615 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Bought by Mackenzie Financial Corp
marketbeat.com - April 18 at 6:30 AM
TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Rating of "Moderate Buy" from BrokeragesTransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Rating of "Moderate Buy" from Brokerages
americanbankingnews.com - April 18 at 2:32 AM
TransMedics Group (NASDAQ:TMDX) Stock Price Down 6.1%TransMedics Group (NASDAQ:TMDX) Stock Price Down 6.1%
marketbeat.com - April 17 at 2:16 PM
Validea Detailed Fundamental Analysis - TMDXValidea Detailed Fundamental Analysis - TMDX
nasdaq.com - April 17 at 8:57 AM
TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024
finance.yahoo.com - April 16 at 8:10 PM
TransMedics (TMDX) Flat As Market Sinks: What You Should KnowTransMedics (TMDX) Flat As Market Sinks: What You Should Know
zacks.com - April 15 at 7:21 PM
Theres Been No Shortage Of Growth Recently For TransMedics Groups (NASDAQ:TMDX) Returns On CapitalThere's Been No Shortage Of Growth Recently For TransMedics Group's (NASDAQ:TMDX) Returns On Capital
finance.yahoo.com - April 15 at 2:13 PM
Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells 12,000 Shares of StockInsider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells 12,000 Shares of Stock
insidertrades.com - April 14 at 4:20 AM
TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells $1,141,080.00 in StockTransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells $1,141,080.00 in Stock
marketbeat.com - April 12 at 6:32 PM
Wall Street Favorites: 3 Long-Term Stocks With Strong Buy Ratings for April 2024Wall Street Favorites: 3 Long-Term Stocks With Strong Buy Ratings for April 2024
investorplace.com - April 12 at 4:30 PM
TransMedics group exec sells over $1.79 million in company stockTransMedics group exec sells over $1.79 million in company stock
investing.com - April 12 at 9:43 AM
3 Must-Own Stocks for Sustained Growth Over the Next 18 Months3 Must-Own Stocks for Sustained Growth Over the Next 18 Months
investorplace.com - April 12 at 6:30 AM
Tamer I. Khayal Sells 15,512 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) StockTamer I. Khayal Sells 15,512 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock
americanbankingnews.com - April 12 at 4:36 AM
The 3 Most Promising MedTech Stocks to Invest In NowThe 3 Most Promising MedTech Stocks to Invest In Now
investorplace.com - April 11 at 2:55 PM
Heart And Lung Transplants Drive Medical Stock Higher As S&P 500 FizzlesHeart And Lung Transplants Drive Medical Stock Higher As S&P 500 Fizzles
finance.yahoo.com - April 11 at 2:12 PM
Organ Transplant Stock Surges Past Buy Point Even As S&P 500 FizzlesOrgan Transplant Stock Surges Past Buy Point Even As S&P 500 Fizzles
investors.com - April 11 at 10:55 AM
TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Peregrine Capital Management LLCTransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Peregrine Capital Management LLC
marketbeat.com - April 11 at 7:49 AM
Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 15,512 Shares of StockInsider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 15,512 Shares of Stock
insidertrades.com - April 11 at 6:37 AM
TransMedics Group (NASDAQ:TMDX) Trading Up 2%TransMedics Group (NASDAQ:TMDX) Trading Up 2%
marketbeat.com - April 10 at 2:51 PM
Moody Aldrich Partners LLC Buys 24,290 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)Moody Aldrich Partners LLC Buys 24,290 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)
marketbeat.com - April 9 at 1:32 PM
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
prnewswire.com - April 8 at 4:05 PM
Kent Lake Capital LLC Has $4.34 Million Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)Kent Lake Capital LLC Has $4.34 Million Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)
marketbeat.com - April 6 at 7:36 PM
TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $397,540.92 in StockTransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $397,540.92 in Stock
insidertrades.com - April 6 at 7:39 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BioLife Solutions logo

BioLife Solutions

NASDAQ:BLFS
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Natus Medical logo

Natus Medical

NASDAQ:NTUS
Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and technologies used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing assessment, screening, and instrument fitting solutions; jaundice management products; brain injury products; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. Additionally, it offers essential products used in the everyday operation of neonatal intensive care unit (NICU); balance assessment systems to evaluate patients with balance disorders; and NICVIEW, a live streaming video for families with babies in the NICU. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation for hearing and balance care professionals. It serves university medical centers, public and private hospitals, physician offices, clinics, research laboratories, and others. The company was formerly known as ALGOTEK Instruments, Inc. and changed its name to Natus Medical Incorporated in September 1988. Natus Medical Incorporated was incorporated in 1987 and is headquartered in Middleton, Wisconsin.
Outset Medical logo

Outset Medical

NASDAQ:OM
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
TransMedics Group logo

TransMedics Group

NASDAQ:TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.